Everest Medicines (FRA:6HN) Institutional Ownership: 16.90% (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6HN Everest Medicines Ltd FRA:6HN
43 GF Score
Price €4.04
GF Value €27.16
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Everest Medicines Institutional Ownership?

Everest Medicines FRA:6HN +61.60% 43 Institutional Ownership is 16.90% as of Aug. 21, 2026. GuruFocus rates FRA:6HN with a GF Score™ of 43/100 and a GF Value™ of €27.16 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Everest Medicines's institutional ownership is 16.90%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Everest Medicines's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Everest Medicines's Float Percentage Of Total Shares Outstanding is 0.00%.

Everest Medicines Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Everest Medicines's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Everest Medicines Institutional Ownership Chart

Everest Medicines Historical Data

The historical data trend for Everest Medicines can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 14.27 14.61 16.90 17.12 17.14 16.94 16.99 16.96 16.81 16.90
FRA:6HN
43GF Score
Everest Medicines Ltd FRA:6HN
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Everest Medicines Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 16.90% mean?
Everest Medicines (FRA:6HN) has a Institutional Ownership of 16.90% as of Aug. 21, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Everest Medicines and its competitors.
Is Everest Medicines' Institutional Ownership too high?
Everest Medicines' current Institutional Ownership is 16.90%. Overall, Everest Medicines has a GF Score™ of 43/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Institutional Ownership compare to VRTX and REGN?
Everest Medicines' Institutional Ownership of 16.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Everest Medicines and its competitors. Everest Medicines's current Institutional Ownership is 16.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (FRA:6HN) is currently considered Significantly Undervalued. The stock's GF Value™ is €27.16, compared to a current price of €4.04 — trading 85.1% below its estimated fair value. The current Institutional Ownership is 16.90%. Everest Medicines' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Everest Medicines (FRA:6HN), the current Institutional Ownership is 16.90% as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Everest Medicines (FRA:6HN) Overvalued in 2026?

Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued. The current stock price of €4.04 is trading 85.1% below its estimated GF Value™ of €27.16. GuruFocus considers Everest Medicines to be Significantly Undervalued.

Key valuation signals for FRA:6HN:

  • Institutional Ownership: 16.90%
  • GF Value™: €27.16 vs. price of €4.04 (85.1% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the FRA:6HN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Everest Medicines Business Description

Other Exchanges 01952:Hong Kong6HN:Germany
Address AIA Financial Center, 866 East Changzhi Road, 17th Floor, Hongkou District, Shanghai, CHN, 200082
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
43GF Score

Get the complete analysis for FRA:6HN

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.04
Price
€27.16
GF Value